Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: MJ who wrote (1107)	10/11/1998 3:51:00 PM
From: John S. Baker	Read Replies (1) \| Respond to of 1510

"Is it possible that the IMNR treatment for AIDS could be the opening of the door for treating other viruses in a similar fashion. Or even a bridge to treating other diseases whose end results are similar in nature---i.e. the breakdown of the autoimmune system." I am not a medical expert ... just a long-term IMNR shareholder ... but a recent company presentation leads me to believe that the key element is the company's approach (my word). This approach might be expected to be effective in many other areas of study. ---- I don't know enough about the origin of AIDS to respond to your other question ... except to note that people rarely died of cancer 100 years ago. They usually died of something else first. Genetics can be a strange thing. JSb.

To: MJ who wrote (1107)	10/11/1998 4:45:00 PM
From: nord	Respond to of 1510

Is it possible that the IMNR treatment for AIDS could be the opening of the door for treating other viruses in a similar fashion. Or even a bridge to treating other diseases whose end results are similar in nature---i.e. the breakdown of the autoimmune system. If so, this stock could be a winner on many levels. A second question ---is AIDS a new disease of this late century or is it a disease such as polio which according to a recent documentary is thought to be centuries old and became prevalent in the early part of this century and later in the 1950's in this country as we began to improve sanitation. the possibilities for the type of therapy being developed by imnr is well documented on the website pipeline and this is just the start. which of these will prove to effect the natural histrory of disease be they infectious or autoimmune or malignancy awaits results of further study AIDS is clearly a new disease although the exact date it was first infecting persons in the US is still open to debate there is evidence that it may have begun here as early as the 50's. The transmission of HIV is not through fecal contamination and hence does not directly result from poor sanitation. IMNR is a biopharmaceutical company developing immune-based therapies to induce specific T cell response for the treatment of HIV, autoimmune diseases and cancer. For the six months ended 6/98, revenues totalled $11.7 million, up from $1 million. Net loss applicable to Common decreased 63% to $6.6 million. Revenues reflect licensed research revenues received from Agouron. Lower loss reflects the absence of initial costs related to clinical trials.